About UsAbout_Us.htmlshapeimage_3_link_0
Investor RelationsInvestor_Information.htmlshapeimage_4_link_0
About UsNews.htmlshapeimage_5_link_0
About UsContact_Us.htmlshapeimage_6_link_0
Investor RelationsScience.htmlshapeimage_7_link_0
NewsProduct_Development.htmlshapeimage_8_link_0

» About Us

» Our Mission

» Business Strategy

» Management

» Board of Directors

TROV.PK

TrovaGene Inc., 11055 Flintkote Ave., Suite B, San Diego, CA 92121

shapeimage_11_link_0
Investor Relations
NewsContact_Us.htmlshapeimage_11_link_0

  1. ‣Thomas Adams, Ph.D.

    Chairman of the Board


  1. ‣Since June 2005, Dr. Adams has served as a director of IRIS International, Inc., a diagnostics company, and as Chief Technology Officer of IRIS since April 2006. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006, when Leucadia was acquired by IRIS. In 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Before founding Gen-Probe, Dr. Adams held management positions at Technicon Instruments and the Hyland Division of Baxter Travenol. He has significant public-company experience serving as a director of Biosite Diagnostics, Inc., a publicly held medical research firm, from 1989 to 1998 and as a director of Invitrogen, a publicly held company that develops, manufactures and markets research tools and products, from 2000 to 2002. Dr. Adams currently serves as a director of La Jolla Pharmaceutical Co. (NASDAQ: LJPC), a publicly held company that develops and markets novel therapeutics for antibody-mediated autoimmune diseases. Thomas H. Adams, Ph.D has also been a Director of Synergy Pharmaceuticals since July 2008.

  2. ‣Dr. Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside.


  1. ‣Gary Jacob, Ph.D.

    Director


  1. ‣Gary S. Jacob, Ph.D. also serves as President, Chief Executive Officer and a Director of Synergy Pharmaceuticals since July 2008 and as Chairman of Synergy from October 2003 until July 2008. 

  2. ‣Dr. Jacob currently also serves as Chief Executive Officer and a Director of Callisto Pharmaceuticals, Inc.. Prior to his involvement with Callisto and Synergy, Dr. Jacob was at Monsanto/G.D. Searle, where he served as Director of Glycobiology and Monsanto Science Fellow, specializing in the field of Glycobiology and drug discovery. From 1986 to 1990, Dr. Jacob managed the G.D. Searle Glycobiology Group located at Oxford University, England.

  3. ‣Dr. Jacob earned a B.S. in Chemistry from the University of Missouri, and holds a PH.D. in Biochemistry from the University of Wisconsin–Madison.


  1. ‣John P. Brancaccio, C.P.A.

    Director


  1. ‣John P. Brancaccio, a retired CPA, has also served as a Director of Synergy Pharmaceuticals since July 2008. Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies.

  2. ‣From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. Mr. Brancaccio is currently a director of Alfacell Corporation as well as a director of Callisto Pharmaceuticals, Inc.


  1. ‣Gabriele Cerrone, M.B.A

    Director


  1. ‣Gabriele M. Cerrone has served as our Chairman of the Board of Directors since July 2008.

  2. ‣From March 1999 to January 2005 Mr. Cerrone served as a Senior Vice President of Investments of Oppenheimer & Co. Inc., a financial services firm. Prior to such affiliation, Mr. Cerrone held the position of Managing Director of Investments at Barrington Capital, L.P., a merchant bank, between March 1998 and March 1999.  Mr. Cerrone was also a founder of FermaVir Pharmaceuticals, Inc., a biotechnology company, and served as Chairman from 2005 to 2007, when the company was acquired by Inhibitex, Inc., a biotechnology company.  Mr. Cerrone was also a founder of Xenomics, Inc., a diagnostic company, and served as Chairman from 2004 until 2006.  Mr. Cerrone currently serves as a director of Inhibitex, Inc. and as Chairman of Callisto Pharmaceuticals, Inc.  From 2001 to 2003, Mr. Cerrone also served on the board of directors of SIGA Technologies, Inc.  Mr. Cerrone is the managing partner of Panetta Partners Ltd., a Colorado limited partnership investing in both public and private companies in the life sciences and technology arena as well as real estate.

  3. ‣Mr. Cerrone graduated from New York University’s Stern School of Business with a Masters Degree in Finance.


  1. ‣Dr. Stanley Tennant

    Director


  1. ‣Dr. Tennant has served as a director of our company since December 2010.  Since 1983, Dr. Tennant has been a cardiologist in Greensboro, NC. He graduated from Wake Forest University School of Medicine in 1978 and completed postgraduate training in Internal Medicine and Cardiology at Vanderbilt University in 1983.

 

TROVAGENE INC (TROV.PK)